Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis. — SELECT-sJIA

Juvenile Idiopathic Arthritis Clinical Trial

Official title:
A Multicenter, Randomized Open-Label Study to Assess the Efficacy, Safety, and Pharmacokinetics of Upadacitinib With a Tocilizumab Reference Arm in Subjects From 1 Year to Less Than 18 Years Old With Active Systemic Juvenile Idiopathic Arthritis

Status Recruiting

Clinical Trial Summary

Juvenile Idiopathic Arthritis (JIA) is the most common type of arthritis that affects children. The term "idiopathic" means "of unknown origin". It is a chronic (long-lasting) disease that causes swelling, warmth, and pain of one or more small joints. Systemic JIA ia a rare and serious form of JIA. Systemic" means it may affect not only the joints but other parts of the body, including the liver, lungs and heart. sJIA is more severe and can be more challenging to diagnose and treat than other types of juvenile idiopathic arthritis. It is a lifelong disease for many patients and can continue into adulthood. This study will assess how safe and effective upadacitinib is in treating pediatric and adolescent participants aged 1 to < 18 with systemic juvenile idiopathic arthritis (sJIA) and will include a tocilizumab treatment arm for reference. Adverse events and change in the disease activity will be assessed. Upadacitinib is an investigational drug being developed for the treatment of sJIA. Participants are assigned to 1 of 2 cohorts. In cohort 1, participants will receive upadacitinib or tocilizumab reference. In cohort 2, participants will receive upadacitinib. Approximately 90 participants with sJIA will be enrolled in approximately 45 sites worldwide. Participants will receive upadacitinib oral tablets once daily or oral solution twice daily or tocilizumab subcutaneous injection or intravenous infusion as per local label for 52 weeks and followed for approximately 30 days. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits/calls during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, checking for side effects and completing questionnaires.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05609630
Study type	Interventional
Source	AbbVie
Contact	ABBVIE CALL CENTER
Phone	844-663-3742
Email	abbvieclinicaltrials@abbvie.com
Status	Recruiting
Phase	Phase 3
Start date	October 2, 2023
Completion date	June 19, 2029

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02776735` - An Open-label, Ascending, Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA)	Phase 2
Active, not recruiting	`NCT03092427` - Probiotic Treatment in Juvenile Idiopathic Arthritis (JIA)	N/A
Not yet recruiting	`NCT05545098` - MSUS Versus Serum Survivin and Lubricin Levels in Evaluation of Disease Activity in JIA
Not yet recruiting	`NCT03833609` - Yoga and Aerobic Dance for Pain Management in Juvenile Idiopathic Arthritis	N/A
Completed	`NCT02524340` - Patient Centered Adaptive Treatment Strategies Using Bayesian Causal Inference
Recruiting	`NCT01434082` - Sleep Patterns in Children With and Without Juvenile Idiopathic Arthritis	N/A
Completed	`NCT04671524` - The Effect of Improvement in Function on Foot Pressure, Balance and Gait in Children With Upper Extremity Affected	N/A
Recruiting	`NCT04167488` - Assessment of Physical Activity Among Juvenile Idiopathic Arthritis Children Performed With Actigraphy	N/A
Recruiting	`NCT04205500` - Treatment With Specific Carbohydrate Diet in Children With Juvenile Idiopathic Arthritis	N/A
Terminated	`NCT01694264` - Study of Anti-Viral Prophylaxis for HBsAg(+) or HBcAb(+)/HBsAb(-) Patients Starting Anti-TNFα	Phase 3
Completed	`NCT02824978` - Therapeutic Alliance is it Associated With Better Compliance Amongst Children With Juvenile Idiopathic Arthritis ?
Active, not recruiting	`NCT03841357` - Preventing Extension of Oligoarticular Juvenile Idiopathic Arthritis JIA (Limit-JIA)	Phase 3
Completed	`NCT03833271` - The Efficacy of Influenza Vaccine Program in Children With Juvenile Idiopathic Arthritis. A Single Centre Results From Hungary	Early Phase 1
Completed	`NCT01455701` - A Study to Evaluate Pharmacokinetics and Safety of Tocilizumab (RoActemra/Actemra) in Participants Less Than 2 Years Old With Active Systemic Juvenile Idiopathic Arthritis (sJIA)	Phase 1
Completed	`NCT05031104` - Low-energy Laser Applications in Patients With Juvenile Idiopathic Arthritis	N/A
Not yet recruiting	`NCT01436019` - Study of Antibodies to Anti-TNF Agents in Juvenile Idiopathic Arthritis	N/A
Recruiting	`NCT05696340` - Access to Pediatric Rheumatology Centers for JIA Patients: Factors Associated With Time to Access Pediatric Rheumatology Centers
Recruiting	`NCT05545839` - Transition to Adulthood Through Coaching and Empowerment in Rheumatology	N/A
Completed	`NCT05436301` - Turkish Validity and Reliability of Pain Catastrophizing Scale-Child (PCS-C)
Not yet recruiting	`NCT05467579` - Mandibular Advancement Clear Aligner Treatment in Juvenile Idiopathic Arthritis Subjects	N/A